Slides
Page 1
INVESTOR PRESENTATION October 2026
Page 2
Aarti Pharmalabs Limited 2 SNAPSHOT 220+ Products 65 Patents Filed 7 Manufacturing Units 3 USFDA Units 15-20% Global Market Share in Xanthine 500+ Global Clients 50+ Export Countries 2,500+ Employees 3 State-of-the-art R&D facilities 60 US DMF 44 CEP AA- Credit rating Net Debt/Equity0.37x 25 Years of Pharmaceutical Excellence
Page 3
Aarti Pharmalabs Limited 1 COMPANY OVERVIEW 2 3 4 BUSINESS OVERVIEW STRATEGIC OVERVIEW FINANCIAL OVERVIEW
Page 4
Aarti Pharmalabs Limited 4 COMPANY OVERVIEW • Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 145+ bn (FY26) • Globally recognized manufacturer of generic API, Xanthine derivatives (Worlds third largest capacity) and a leading player in CDMO/CMO services • Demonstrated strong expertise in development of robust & cost-effective process for rapid scale up and commercial production • Received accreditation from several agencies, including USFDA, EU GMP, EDQM (European Pharmacopoeia), KFDA (Korea), and COFEPRIS (Mexico) • Strategically located in western India with proximity to ports HIGHLIGHTS One of the leading small molecule CDMO/CMO company in India. Regulatory focussed operations with expertise in novel chemistries; Largest manufacturer of Xanthine Derivatives in India International, 61% Domestic, 39% GEOGRAPHICAL SALES (H1-FY27) 15,021 17,714 17,976 11,472 23.0% 24.0% 22.6% 23.4% FY24 FY25 FY26 H1-FY27 STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%)
Page 5
Aarti Pharmalabs Limited 5 KEY MILESTONES 1984 Aarti Organic Private Limited was incorporated 2001 Commissioned the first API manufacturing unit in Dombivli (Unit 1) and started the Xanthine unit 2005 Commissioned the first API manufacturing unit in Tarapur for Regulated Markets (Unit 4) 2008 Successfully completed the USFDA & EUGMP audit for Tarapur Unit 4 2009 Successfully completed the USFDA audit at the Intermediate facility (CSD) in Vapi 2013 Received EUGMP approval for Bicalutamide for the Oncology block at Unit 4 2016 Commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tons (MT) per month 2019 Successfully completed an audit by EDQM for Bicalutamide for the Oncology block at Unit 4 2022 • Expanded block for CSD in Vapi and API in Tarapur units • Acquired land at Atali for future growth • Successfully demerged the pharmaceutical business of Aarti Industries Limited to Aarti Pharmalabs Limited 2023 • Operationalized the third R&D center • Secured USFDA approval for Dombivli Unit • Commercialized Block V at Tarapur Unit 4 • Enhanced Xanthine capacity to 5,000 TPA 2024 • Started 21 MW solar power project at Akola, Maharashtra • Expansion of semi-commercial production block at Vapi 2025 Commissioned Phase 1 at Atali greenfield site with 450+ kL reactor capacity 1 2 3 4 5 6 7 8 9 10 11 12 13 2026 • Inaugurated Tarapur(Unit 5), adding 3,600 TPA to reach a total capacity of 9,600 TPA